Articles tagged with Drug Targets
Researchers found a new treatment approach that targets the body's cellular response to SARS-CoV-2, significantly reducing virus replication. The combination of two drugs reduces virus production in cells by up to 99.5%, making COVID-19 symptoms milder and recovery times faster.
Researchers at Northwestern University have identified a novel target for a drug to treat SARS-CoV-2 and potential future coronaviruses. The new therapy could be taken early in the disease to prevent severe symptoms.
Scientists at Rockefeller University have identified a new class of therapeutics that destroy fibrolamellar tumor cells growing in mice. The team tested over 5,000 compounds to find these effective treatments, which could potentially transform the landscape of precision medicine by tailoring treatment options for individual patients
A live-cell screening strategy identified Kv7.2/7.3 as a key target for treating hyperexcitability-induced neurodegeneration in ALS patients. QurAlis' therapeutic candidate QRL-101 (QRA-244) shows promise in decreasing spinal and cortical motor neuron excitability.
A new study by Ludwig Institute researchers has developed a method to quickly identify potentially effective drug combinations for personalized cancer therapy. By using dynamic BH3 profiling, the team found specific metabolic dependencies in triple-negative breast cancer cells that could be targeted with existing drugs.
Researchers have identified a potential new treatment for ALS using motor neurons created from ALS patients. The high-throughput platform confirmed two known targets and found an existing class of drugs that could reduce hyperexcitability, a key feature of the disease.
Researchers have developed a new categorization system for vasculitis based on its underlying immunological causes, which may lead to more effective treatments and better patient outcomes. The study identified key differences in disease response to various treatments, paving the way for new clinical trials.
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
University of Minnesota Medical School researchers found that senescent immune cells drive tissue damage and shorten lifespan. The team identified these cells as the most dangerous type of senescent cell, paving the way for developing senolytic drugs targeting them.
Chemists create supramolecular cage using Pd6(TPT)4 cages that can transport and release pharmaceutically active molecules like ibuprofen and progesterone. The system uses ultrasonification to break the bonds, releasing the drugs at the desired location.
Researchers will use whole genome sequencing to identify genetic variants associated with plaques and tangles in the brain, which begin accumulating years before symptoms appear. The goal is to develop early diagnosis methods and potential treatments for Alzheimer's disease.
A new study published in Blood Advances has identified a gene variant, mesothelin (MSLN), that is abnormally expressed in more than one-third of childhood and young adult AML cases. This discovery could lead to the development of precision medicine treatments for children with AML.
A new compound AAZ-A-154 has been identified with potential to act on beneficial pathways in the brain without hallucinogenic effects. The discovery was made possible by a genetically encoded fluorescent sensor called psychLight that screens for hallucinogenic potential.
Researchers at NUS have identified two new proteins that contribute to EV-A71's ability to invade the central nervous system, making them potential targets for treating severe HFMD cases. This discovery could lead to the development of more effective treatments, particularly for young children affected by this illness.
The company's Abiprot technology identifies antibody binding sites on native-state, disease-relevant proteins at high resolution. The platform has the potential to bring game-changing benefits to large populations of patients suffering from uncurable diseases.
Researchers at Tokyo Medical and Dental University developed an antibody-drug conjugate that selectively targets human monocyte progenitors to combat chronic myelomonocytic leukemia (CMML). This strategy effectively blocks malignant cell proliferation with minimal collateral damage to other cell lineages.
Scientists have discovered how a unique molecular switch in the brain causes feelings of fullness and may help develop improved anti-obesity drugs. The melanocortin receptor 4 is activated by setmelanotide, which binds to its binding pocket and enhances binding with calcium ions.
A new study suggests prioritizing clinical trials of drugs targeting these two proteins to manage COVID-19 in its early stages. Researchers used large-scale human genetic studies to identify existing drugs that can be repurposed for the treatment.
Researchers discovered a biochemical pathway triggered by SARS-CoV-2 in lung cells, which may explain the disease's difficulty to treat. The pairing of antiviral drugs with inhibitors of this process showed promise in inhibiting the immune response.
Researchers identified Mycobacterium tuberculosis' use of rubredoxin B to survive in iron-deficient conditions, helping the bacterium evade the immune system. The study provides new insights into the development of drug resistance and potential targets for therapeutic agents.
A team of University of Alberta researchers has identified a protein that blocks the body's ability to clear low-density lipoprotein (LDL) cholesterol from the blood. This discovery paves the way for developing a new drug to boost existing statin drugs and prevent heart disease.
Researchers at NYU Langone Health identified hundreds of potential new treatment targets for epilepsy by analyzing adult human brain tissue. Altered levels of brain proteins were found predominantly in the hippocampus and frontal cortex, suggesting that these regions may play a role in the development of the disorder.
A breakthrough discovery has pinpointed the mechanism by which normal proteins convert to diseased forms, causing conditions like CJD and Kuru. The research could lead to the development of new drugs to combat these devastating diseases.
Researchers discover histone-lysine N-methyltransferase (NSD3) as a main driver of squamous cell carcinoma lung cancer. Targeting NSD3 could improve treatment and survival rates.
A team at Massachusetts General Hospital developed an artificial intelligence-based method to screen currently available medications as possible treatments for Alzheimer's disease. The analysis yielded a ranked list of candidates, including anti-inflammatory drugs used to treat rheumatoid arthritis and blood cancers.
A new study by Johns Hopkins Bloomberg School of Public Health found that Medicare Part D program lost $1.7 billion due to requests for brand name over generic prescription drugs in 2017. Opting for generic drugs could save hundreds of millions annually.
A team of international researchers has discovered a promising therapeutic drug target, SARM1, which is activated in response to nerve fibre damage. This finding offers hope for developing effective treatments for neurodegenerative disorders such as Parkinson's and Alzheimer's disease.
Researchers at Hong Kong Baptist University develop a peptide-linked drug targeting two viral proteins produced by Epstein-Barr virus, reducing cancer cell damage and increasing drug uptake rates. The novel drug has shown efficacy in animal models and is being further developed for clinical trials.
Researchers are exploring a novel approach to target disease-causing proteins in human cells. This method, utilizing ubiquitin ligases, aims to overcome traditional drug discovery limitations by targeting more disease-causing proteins, offering new therapeutic possibilities for various conditions.
A machine-learning approach has been developed to identify repurposed drugs for COVID-19 treatment in elderly patients. The system accounts for changes in gene expression in lung cells caused by both the disease and aging, pinpointing the protein RIPK1 as a promising target.
The combination of lenvatinib and pembrolizumab significantly improved overall survival, progression-free survival, and response rates compared to sunitinib in untreated patients with metastatic kidney cancer. The study results demonstrate the importance of immune checkpoint inhibitors in first-line treatment.
A new class of antibiotic-drug conjugate (ADC) drugs has been found to significantly increase the survival rate of patients with bladder cancer. The study, led by Queen Mary University of London, showed that the drug reduced the risk of death by 30% compared to chemotherapy, with a median survival time of approximately 13 months.
A recent study found that protected areas reduce the rate of deforestation by 41%, but nearly one-third of these areas are under intense human pressure. The study suggests that just 6.5% of the Earth's woodlands are truly protected, well below the UN's 2020 target of 17%.
Researchers at UT Health San Antonio have identified a human protein called SAMHD1 that can recognize and respond to the HIV virus. This recognition mechanism may lead to a new approach for treating HIV/AIDS by targeting the protein with a specific drug.
A new biologically active porphyrin compound was isolated from Ophiura sarsii, which may be used to make photodynamic therapy more affordable. The compound has been shown to have antitumor effects and could potentially be used to treat triple-negative breast cancer and other cancers.
A University of Colorado Boulder study suggests that existing PARP inhibitors for hereditary breast and ovarian cancers may not work as intended. The research reveals a previously unknown interaction between the PARP protein and HPF1, which could lead to more effective treatments by targeting this co-protein.
A new study from Boston University School of Medicine has discovered a drug that can inhibit the growth and spread of melanoma in human cells and experimental models. The researchers found that this drug acts through a specific pathway to prevent cancer cell growth and metastasis.
A team of international researchers found that certain FAK inhibitors remain bound to the protein for a long time, causing a structural change that inhibits cancer cell mobility. Computer simulations predicted the kinetics of binding well, allowing for more accurate simulation of drug dissociation rates.
Researchers found that nitisinone is toxic to tsetse flies but harmless to pollinator insects. The study suggests using the approved drug as an eco-friendly strategy to control trypanosomiasis transmission.
OHIO researchers have identified a potential target for anti-viral drugs to battle COVID-19 by disrupting the viral RNA's ability to reproduce. The team found that a specific section of the RNA, called stem-loop II motif, is highly conserved and essential for the virus's replication.
A new drug targeting enzymes involved in myristoylation has shown promise in treating both breast and blood cancers. Researchers found that patients with specific enzyme NMT2 were more likely to die, and the drug slowed tumour growth by 90% in mice with human breast cancer.
A new nasal spray delivery method promises relief from antipsychotic medication's adverse side effects by delivering medication directly to the brain. This approach could reduce required doses by as much as three quarters, sparing patients from debilitating side effects and improving treatment efficacy.
Scientists at Wits University infected mosquitoes with human malaria and identified a new chemical compound that shows promise in treating the disease. The study, published in Nature Communications, aimed to develop a drug that can block both human-to-mosquito transmission and mosquito-to-human transmission.
A new study stratified tumors into 112 subtypes and found Master Regulator proteins control the transcriptional state of each subtype. Targeting these proteins with novel drug classes could benefit a larger fraction of patients. The analysis identified 24 Master Regulator modules, mechanistically controlling cancer cell survival.
Researchers found that decreased activation of gene LEF1 disrupts neuronal function and promotes hyperexcitability in brain cells, a hallmark of bipolar disorder. Increasing LEF1 expression may lead to new drug targets and biomarkers for lithium nonresponsiveness.
Researchers developed a novel method to discover ligands and inhibitors against membrane proteins, which are challenging to target. The method uses DNA-programmed affinity labelling and boosting sequences to improve screening specificity and abundance.
Researchers at UTHealth have discovered a gene signaling pathway linked to schizophrenia using human-induced pluripotent stem cells. The PI3K/GSK3 pathway was found to be dysregulated in neurons from patients with schizophrenia, with SGK1 inhibitor being associated with the condition.
A new study has identified and characterized neurons that regulate nausea-like responses in mice, shedding light on the sensation of nausea. The findings reveal a division of labor between area postrema neurons, with different neuron types responsible for detecting and raising the alarm for various substances.
A study has identified five genes associated with severe COVID-19, which could lead to the development of new treatments. The genes, IFNAR2, TYK2, OAS1, DPP9 and CCR2, are involved in antiviral immunity and lung inflammation processes.
Scientists create peptide-oligourea hybrids that mimic natural peptide structures, enhancing drug efficiency and stability. The hybrids exhibit high binding affinities and resist proteolytic degradation.
Researchers are using cutting-edge technology to analyze immune cell interactions in lupus patients, identifying potential targets for new therapies. The Lupus Mechanisms and Targets Award will support innovative studies aimed at improving diagnostics and treatments for the disease.
Researchers have identified a population of brain cells in the amygdala linked to physiological arousal responses, which can drive symptoms of anxiety disorders. These findings suggest that targeting these neurons may lead to new treatments for psychiatric illnesses.
A novel drug target has been identified for neonatal and infant heart failure, a condition with no specific treatment. The target stimulates cardiac contractility in newborns and infants with minimal side effects, offering new possibilities for pediatric heart failure treatment.
The December special issue of SLAS Discovery focuses on drug discovery efforts for COVID-19, including reviews on repurposing drugs and testing novel proteins necessary for virus replication. The issue also includes articles on the efficacy of existing treatments and potential off-label candidates.
Researchers at Michigan State University have identified a potential genetic target for treating an especially painful and invasive form of endometriosis. They discovered that targeting super-enhancers, altered by a mutation in the ARID1A gene, could lead to effective treatment using epigenetic therapy.
Researchers have identified a unique population of CD38hiCD127- CD8 T cells in patients with checkpoint inhibitor-induced arthritis, which are both cytotoxic and proliferating. This discovery could lead to the development of targeted treatments for this side effect.
Researchers discovered that overexpressing protein kinase A (PKA) improves muscle resistance to fatigue in mice by suppressing FoxO proteins and increasing oxidative potential. This study offers a potential solution for treating atrophy and promoting muscle growth without severe side effects.
Researchers have discovered a potential broad-spectrum anti-viral drug target by identifying how encapsulated viruses hijack the protein manufacturing and distribution pathways in cells. This approach offers an attractive alternative to developing individual drugs for each virus, with the same compound targeting multiple viruses.
Centenary Institute scientists discovered that two key proteins involved in blood clotting and immunity exist in multiple disulphide-bonded states. This finding has significant implications for drug development and the fight against disease, as different states of a protein may bind more or less preferentially to drugs.
Professor Robert Prud'homme at Princeton University has been awarded the inaugural Dean for Research Award for Distinguished Innovation for his invention of flash nanoprecipitation, a technique that promises to improve drug delivery. The award recognizes Prud'homme's innovative approach to solving critical challenges in society.